Maeyama T, Hashimoto M, Ogawa K, Hanamure Y, Kiyota R, Kurono Y, Iida F, Ohhori Y, Ogawa K
Jpn J Antibiot. 1983 Oct;36(10):2813-9.
On the 53 patients with ENT (ears, nose, and throat) diseases, ototoxicity after intravenous drip infusion of amikacin (Biklin AMK) was studied. Each dose of AMK was 400 mg/day in adults and 4--8 mg/kg/day in children. From audiometric analysis, there were no patients with any hearing disturbances and subjective complaints concerning labyrinth injury. Also abnormal laboratory findings were not found in them. An intravenous drip infusion of AMK in adequate dosage would be beneficial to use against some infectious diseases of otorhinolaryngologic field.
对53例耳鼻喉科疾病患者进行了静脉滴注阿米卡星（Biklin AMK）后的耳毒性研究。成人每次阿米卡星剂量为400毫克/天，儿童为4-8毫克/千克/天。通过听力测定分析，未发现有任何听力障碍的患者，也没有关于迷路损伤的主观主诉。他们的实验室检查结果也未发现异常。以适当剂量静脉滴注阿米卡星有助于治疗耳鼻喉科领域的某些传染病。
